Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response - PubMed
3 hours ago
- #CAR T-cell therapy
- #Hematopoiesis
- #Leukapheresis
- Impaired hematopoiesis in heavily pretreated patients leads to reduced T-cell yields and collection efficiency during leukapheresis.
- Pre-apheresis lymphocyte count strongly predicts CD3+ T-cell yield and is associated with treatment response in CAR T-cell therapy.
- Intensive prior therapies, including stem cell transplantation, reduce CAR T-cell expansion during manufacturing, affecting product quality.
- In ALL patients, higher proportions of effector and CD8+ CAR T-cells in the product correlate with improved clinical outcomes.
- Early leukapheresis before intensive treatments is crucial to optimize T-cell yield, product composition, and therapeutic efficacy.